CY1123776T1 - METHODS OF TREATING CONDITIONS ASSOCIATED WITH MASP-2-INDEPENDENT COMPLEMENT ACTIVATION - Google Patents

METHODS OF TREATING CONDITIONS ASSOCIATED WITH MASP-2-INDEPENDENT COMPLEMENT ACTIVATION

Info

Publication number
CY1123776T1
CY1123776T1 CY20201101069T CY201101069T CY1123776T1 CY 1123776 T1 CY1123776 T1 CY 1123776T1 CY 20201101069 T CY20201101069 T CY 20201101069T CY 201101069 T CY201101069 T CY 201101069T CY 1123776 T1 CY1123776 T1 CY 1123776T1
Authority
CY
Cyprus
Prior art keywords
masp
complement activation
methods
conditions associated
treating conditions
Prior art date
Application number
CY20201101069T
Other languages
Greek (el)
Inventor
Gregory A. Demopulos
Thomas Dudler
Hans-Wilhelm Schwaeble
Original Assignee
Omeros Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Omeros Corporation filed Critical Omeros Corporation
Publication of CY1123776T1 publication Critical patent/CY1123776T1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Dermatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
  • Photoreceptors In Electrophotography (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Σε μία άποψη, η εφεύρεση παρέχει μεθόδους αναστολής των επιδράσεων της εξαρτώμενης από MASP-2 ενεργοποίησης συμπληρώματος σε ένα ζωντανό άτομο που πάσχει ή κινδυνεύει να αναπτύξει θρομβωτική μικροαγγειοπάθεια (ΤΜΑ). Οι μέθοδοι περιλαμβάνουν το στάδιο χορήγησης, σε ένα άτομο που το έχει ανάγκη, μιας ποσότητας ενός ανασταλτικού παράγοντα MASP-2 αποτελεσματικού για την αναστολή της εξαρτώμενης από MASP-2 ενεργοποίησης συμπληρώματος. Σε ορισμένες πραγματοποιήσεις, ο ανασταλτικός παράγοντας MASP-2 αναστέλλει τον κυτταρικό τραυματισμό που σχετίζεται με την ενεργοποίηση εναλλακτικής οδού συμπληρώματος μεσολαβούμενης από MASP-2, ενώ αφήνει ανέπαφο το κλασικό (εξαρτώμενο από Clq) συστατικό της οδού του ανοσοποιητικού συστήματος.In one aspect, the invention provides methods of inhibiting the effects of MASP-2-dependent complement activation in a living subject suffering from or at risk of developing thrombotic microangiopathy (TMA). The methods include the step of administering to a subject in need thereof an amount of a MASP-2 inhibitory agent effective to inhibit MASP-2-dependent complement activation. In some embodiments, the MASP-2 inhibitor inhibits cell injury associated with MASP-2-mediated activation of an alternative complement pathway while leaving intact the classical (Clq-dependent) component of the immune system pathway.

CY20201101069T 2013-10-17 2020-11-11 METHODS OF TREATING CONDITIONS ASSOCIATED WITH MASP-2-INDEPENDENT COMPLEMENT ACTIVATION CY1123776T1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361892283P 2013-10-17 2013-10-17
US201462020845P 2014-07-03 2014-07-03
PCT/US2014/061236 WO2015058143A1 (en) 2013-10-17 2014-10-17 Methods for treating conditions associated with masp-2 dependent complement activation

Publications (1)

Publication Number Publication Date
CY1123776T1 true CY1123776T1 (en) 2022-03-24

Family

ID=52828769

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20201101069T CY1123776T1 (en) 2013-10-17 2020-11-11 METHODS OF TREATING CONDITIONS ASSOCIATED WITH MASP-2-INDEPENDENT COMPLEMENT ACTIVATION

Country Status (24)

Country Link
US (3) US20150166675A1 (en)
EP (2) EP3057993B1 (en)
JP (3) JP2016539919A (en)
KR (3) KR20160062186A (en)
CN (2) CN105683219B (en)
AU (2) AU2014337047B2 (en)
BR (1) BR112016008409B1 (en)
CA (1) CA2926385A1 (en)
CL (2) CL2016000908A1 (en)
CY (1) CY1123776T1 (en)
DK (1) DK3057993T3 (en)
ES (1) ES2829913T3 (en)
HR (1) HRP20201733T1 (en)
HU (1) HUE051746T2 (en)
IL (2) IL283373B2 (en)
LT (1) LT3057993T (en)
MX (2) MX2016005017A (en)
NZ (2) NZ719476A (en)
PL (1) PL3057993T3 (en)
PT (1) PT3057993T (en)
RS (1) RS61351B1 (en)
RU (2) RU2718850C2 (en)
SI (1) SI3057993T1 (en)
WO (1) WO2015058143A1 (en)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8840893B2 (en) 2004-06-10 2014-09-23 Omeros Corporation Methods for treating conditions associated with MASP-2 dependent complement activation
CN103781492A (en) 2011-04-08 2014-05-07 莱斯特大学 Methods for treating conditions associated with MASP-2 dependent complement activation
US9644035B2 (en) 2011-04-08 2017-05-09 Omeros Corporation Methods for treating conditions associated with MASP-2 dependent complement activation
ES2829913T3 (en) 2013-10-17 2021-06-02 Omeros Corp Treatment procedures for conditions associated with MASP-2-dependent complement activation
UA124094C2 (en) * 2015-11-09 2021-07-21 Омерос Корпорейшн Methods for treating conditions associated with masp-2 dependent complement activation
EP3400012A4 (en) * 2016-01-05 2019-12-11 University Of Leicester Methods for inhibiting fibrosis in a subject in need thereof
CN115137816A (en) 2016-03-31 2022-10-04 奥默罗斯公司 Method of inhibiting angiogenesis in a subject in need thereof
JOP20170170B1 (en) * 2016-08-31 2022-09-15 Omeros Corp Highly concentrated low viscosity masp-2 inhibitory antibody formulations, kits, and methods
JOP20190068A1 (en) * 2016-10-13 2019-04-01 Omeros Corp Methods for reducing proteinuria in a human subject suffering from immunoglobulin a nephropathy
TWI818919B (en) * 2017-08-15 2023-10-21 美商歐米諾斯公司 Methods for treating and/or preventing graft-versus-host disease and/or diffuse alveolar hemorrhage and/or veno-occlusive disease associated with hematopoietic stem cell transplant
MX2020002077A (en) * 2017-08-25 2020-03-24 Omeros Corp Highly concentrated low viscosity masp-2 inhibitory antibody formulations, kits, and methods of treating subjects suffering from atypical hemolytic syndrome.
CN108171772B (en) * 2017-12-28 2021-11-19 中国地质调查局西安地质调查中心 Method for extracting river boundary by using mapGIS, CJKCOOR _ Ver and DELF3D
US20200140570A1 (en) * 2018-06-22 2020-05-07 Omeros Corporation Compositions and Methods of Inhibiting MASP-2 for the Treatment of Various Thrombotic Diseases and Disorders
US11161900B2 (en) * 2018-12-13 2021-11-02 Argenx Bvba Antibodies that specifically bind to human complement factor C2b
CN111134250A (en) * 2019-12-03 2020-05-12 海南大学 Formula and preparation method of edible artificial feed for spodoptera frugiperda larvae
US12030853B2 (en) 2019-12-04 2024-07-09 Omeros Corporation MASP-2 inhibitors and methods of use
WO2021113686A1 (en) 2019-12-04 2021-06-10 Omeros Corporation Masp-2 inhibitors and methods of use
JP2023504543A (en) 2019-12-04 2023-02-03 オメロス コーポレーション MASP-2 inhibitors and methods of use
CA3159167A1 (en) 2019-12-04 2021-06-10 Neil S. Cutshall Masp-2 inhibitors and methods of use
CN115215937B (en) * 2021-04-15 2023-05-26 上海麦济生物技术有限公司 Anti-human MASP-2 antibody, preparation method and application thereof
CN115300608B (en) * 2021-05-06 2023-06-02 四川大学 Method for blocking new coronavirus infection by mannose-binding lectin
IL313331A (en) 2021-12-10 2024-08-01 Omeros Corp Therapeutic antibodies that bind to the serine protease domain of masp-2 and uses thereof
US20240228499A1 (en) 2022-11-30 2024-07-11 Omeros Corporation Masp-2 inhibitors and methods of use

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4331647A (en) 1980-03-03 1982-05-25 Goldenberg Milton David Tumor localization and therapy with labeled antibody fragments specific to tumor-associated markers
US4394370A (en) 1981-09-21 1983-07-19 Jefferies Steven R Bone graft material for osseous defects and method of making same
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4526909A (en) 1984-01-09 1985-07-02 Regents Of The University Of California Polymethylmethacrylate delivery system for bone morphogenetic protein
US4563489A (en) 1984-02-10 1986-01-07 University Of California Biodegradable organic polymer delivery system for bone morphogenetic protein
JPH0662679B2 (en) 1985-06-21 1994-08-17 新田ゼラチン株式会社 Tissue-friendly collagen and its manufacturing method
US5453566A (en) 1986-03-28 1995-09-26 Calgene, Inc. Antisense regulation of gene expression in plant/cells
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US4987071A (en) 1986-12-03 1991-01-22 University Patents, Inc. RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods
ATE115999T1 (en) 1987-12-15 1995-01-15 Gene Shears Pty Ltd RIBOZYMES.
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
GB8822492D0 (en) 1988-09-24 1988-10-26 Considine J Apparatus for removing tumours from hollow organs of body
US5211657A (en) 1988-11-07 1993-05-18 The United States Government As Represented By The Secretary Of The Department Of Health And Human Services Laminin a chain deduced amino acid sequence, expression vectors and active synthetic peptides
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5549910A (en) 1989-03-31 1996-08-27 The Regents Of The University Of California Preparation of liposome and lipid complex compositions
EP0438803B1 (en) 1990-01-26 1997-03-12 Immunomedics, Inc. Vaccines against cancer and infectious diseases
JP3218637B2 (en) 1990-07-26 2001-10-15 大正製薬株式会社 Stable aqueous liposome suspension
US5789573A (en) 1990-08-14 1998-08-04 Isis Pharmaceuticals, Inc. Antisense inhibition of ICAM-1, E-selectin, and CMV IE1/IE2
JP2958076B2 (en) 1990-08-27 1999-10-06 株式会社ビタミン研究所 Multilamellar liposome for gene transfer and gene-captured multilamellar liposome preparation and method for producing the same
IL108367A0 (en) 1993-01-27 1994-04-12 Hektoen Inst For Medical Resea Antisense polynzcleotide inhibition of human growth factor-sensitive cancer cells
US5801154A (en) 1993-10-18 1998-09-01 Isis Pharmaceuticals, Inc. Antisense oligonucleotide modulation of multidrug resistance-associated protein
US5856121A (en) 1994-02-24 1999-01-05 Case Western Reserve University Growth arrest homebox gene
US5741516A (en) 1994-06-20 1998-04-21 Inex Pharmaceuticals Corporation Sphingosomes for enhanced drug delivery
JPH10510540A (en) 1994-12-12 1998-10-13 オメロス メディカル システムズ，インコーポレーテッド Irrigation solutions and methods for controlling pain, inflammation and convulsions
US5795587A (en) 1995-01-23 1998-08-18 University Of Pittsburgh Stable lipid-comprising drug delivery complexes and methods for their production
US5738868A (en) 1995-07-18 1998-04-14 Lipogenics Ltd. Liposome compositions and kits therefor
US5739119A (en) 1996-11-15 1998-04-14 Galli; Rachel L. Antisense oligonucleotides specific for the muscarinic type 2 acetylcholine receptor MRNA
EP1200127B1 (en) 1999-07-21 2008-06-25 Omeros Corporation Solutions and methods for inhibition of pain, inflammation and cartilage degradation
US6649592B1 (en) 2000-01-14 2003-11-18 Science & Technology Corporation @ Unm Peptide inhibitors of LFA-1/ICAM-1 interaction
SG98393A1 (en) 2000-05-19 2003-09-19 Inst Materials Research & Eng Injectable drug delivery systems with cyclodextrin-polymer based hydrogels
EP1496835A4 (en) 2002-02-01 2006-10-18 Omeros Corp Compositions and methods for systemic inhibition of cartilage degradation
ES2601143T3 (en) 2002-07-19 2017-02-14 Omeros Corporation Biodegradable triblock copolymers, synthesis methods thereof, and hydrogels and biomaterials prepared therefrom.
ES2629344T3 (en) * 2003-05-12 2017-08-08 Helion Biotech Aps Antibodies against MASP-2
US20050169921A1 (en) 2004-02-03 2005-08-04 Leonard Bell Method of treating hemolytic disease
US7919094B2 (en) 2004-06-10 2011-04-05 Omeros Corporation Methods for treating conditions associated with MASP-2 dependent complement activation
US20130266559A1 (en) * 2004-06-10 2013-10-10 University Of Leicester Methods for Treating Conditions Associated with MASP-2 Dependent Complement Activation
CA3102252A1 (en) * 2004-06-10 2005-12-29 Omeros Corporation Methods for treating conditions associated with masp-2 dependent complement activation
US8840893B2 (en) 2004-06-10 2014-09-23 Omeros Corporation Methods for treating conditions associated with MASP-2 dependent complement activation
EP3121197A1 (en) * 2008-11-10 2017-01-25 Alexion Pharmaceuticals, Inc. Methods and compositions for treating complement-associated disorders
WO2011006982A2 (en) 2009-07-17 2011-01-20 Rigshospitalet Inhibitors of complement activation
BR112012008970A2 (en) 2009-10-16 2019-12-10 Omeros Corp use of a composition and composition
BR112012022214A2 (en) 2010-03-01 2017-07-04 Alexion Pharma Inc methods and compositions for treating degum disease
US20150166676A1 (en) 2011-04-08 2015-06-18 Omeros Corporation Methods for Treating Conditions Associated with MASP-2 Dependent Complement Activation
US9644035B2 (en) * 2011-04-08 2017-05-09 Omeros Corporation Methods for treating conditions associated with MASP-2 dependent complement activation
CN103781492A (en) * 2011-04-08 2014-05-07 莱斯特大学 Methods for treating conditions associated with MASP-2 dependent complement activation
CN107011443B (en) * 2011-05-04 2021-04-30 奥默罗斯公司 Compositions for inhibiting MASP-2 dependent complement activation
JP2013030593A (en) 2011-07-28 2013-02-07 J Devices:Kk Semiconductor devices, semiconductor module structure formed by vertically laminated semiconductor devices, and manufacturing method of semiconductor module structure
EP4119577A3 (en) 2012-06-18 2023-11-08 Omeros Corporation Compositions and methods of inhibiting masp-1 and/or masp-2 and/or masp-3 for the treatment of various diseases and disorders
CN104870475B (en) 2012-10-25 2019-11-08 美国比奥维拉迪维股份有限公司 Anticomplement C1s antibody and its purposes
EP3046581B1 (en) 2013-09-16 2020-04-01 Children's Hospital Medical Center Compositions and methods for treatment of hsct-associated thrombotic microangiopathy
ES2829913T3 (en) 2013-10-17 2021-06-02 Omeros Corp Treatment procedures for conditions associated with MASP-2-dependent complement activation
UA124094C2 (en) 2015-11-09 2021-07-21 Омерос Корпорейшн Methods for treating conditions associated with masp-2 dependent complement activation

Also Published As

Publication number Publication date
EP3057993A4 (en) 2017-09-13
WO2015058143A1 (en) 2015-04-23
IL283373A (en) 2021-07-29
BR112016008409B1 (en) 2021-06-15
US11525011B2 (en) 2022-12-13
KR102677379B1 (en) 2024-06-24
MX2021008044A (en) 2021-10-13
SI3057993T1 (en) 2021-03-31
JP7397037B2 (en) 2023-12-12
CN111588855A (en) 2020-08-28
JP2020037568A (en) 2020-03-12
LT3057993T (en) 2020-11-25
IL283373B1 (en) 2024-04-01
DK3057993T3 (en) 2020-11-16
EP3057993A1 (en) 2016-08-24
AU2014337047B2 (en) 2020-03-12
IL245115B (en) 2022-05-01
HUE051746T2 (en) 2021-03-29
JP2016539919A (en) 2016-12-22
US20200157244A1 (en) 2020-05-21
NZ719476A (en) 2022-07-29
PT3057993T (en) 2020-11-19
PL3057993T3 (en) 2021-02-08
CL2018001557A1 (en) 2018-07-20
AU2020203748A1 (en) 2020-06-25
EP3750919A1 (en) 2020-12-16
RU2016118769A3 (en) 2018-11-21
RU2020111211A (en) 2021-11-08
ES2829913T3 (en) 2021-06-02
US20240124611A1 (en) 2024-04-18
US20150166675A1 (en) 2015-06-18
EP3057993B1 (en) 2020-08-12
MX2016005017A (en) 2016-11-07
KR20220053057A (en) 2022-04-28
KR20240101700A (en) 2024-07-02
BR112016008409A2 (en) 2017-10-03
IL245115A0 (en) 2016-06-30
IL283373B2 (en) 2024-08-01
JP6953498B2 (en) 2021-10-27
RU2718850C2 (en) 2020-04-15
HRP20201733T1 (en) 2021-02-05
CL2016000908A1 (en) 2016-12-02
RU2016118769A (en) 2017-11-22
JP2022000467A (en) 2022-01-04
CA2926385A1 (en) 2015-04-23
AU2014337047A1 (en) 2016-05-19
NZ757986A (en) 2022-07-29
CN105683219A (en) 2016-06-15
RS61351B1 (en) 2021-02-26
AU2020203748B2 (en) 2022-08-04
CN105683219B (en) 2020-07-14
KR20160062186A (en) 2016-06-01

Similar Documents

Publication Publication Date Title
CY1123776T1 (en) METHODS OF TREATING CONDITIONS ASSOCIATED WITH MASP-2-INDEPENDENT COMPLEMENT ACTIVATION
CY1125161T1 (en) 1,2,4-OXADIAZOLE AND THIADIAZOLE COMPOUNDS AS IMMUNO-REGULATORS
CY1122909T1 (en) METHODS OF TREATMENT OF EOSINOPHILIC ESEOPHAGITIS BY ADMINISTRATION OF AN IL-4R INHIBITOR
CY1122631T1 (en) HOLANIS DERIVATIVES FOR USE IN THE TREATMENT AND/OR PREVENTION OF FXR AND TGR5/GRBAR1-MEDIATED DISEASES
CY1123678T1 (en) USE OF MYOSTATIN INHIBITORS AND COMBINATION THERAPIES
CY1122510T1 (en) ANTIBODY MOLECULES TO LAG-3 AND USES THEREOF
EA201791751A1 (en) REGULATION OF GENE EXPRESSION THROUGH APTAMER-MEDIATED MODULATION OF ALTERNATIVE SPLISING
EA201891132A1 (en) METHODS OF TREATMENT OF CONDITIONS ASSOCIATED WITH MASP-2 DEPENDABLE COMPLEMENT ACTIVATION
CY1118696T1 (en) METHODS FOR TREATMENT OF DIPLOMATIC INTELLIGENCE COGLASSIS BY MASP-2 ADDITIONAL INTERVENTION INTERVENTION
CY1120950T1 (en) FIBER TREATMENT
CY1121653T1 (en) C1-INH COMPOSITIONS AND METHODS FOR THE PREVENTION AND TREATMENT OF DISORDERS ASSOCIATED WITH C1 ESTERASE INHIBITOR DEFICIENCY
MD3369425T2 (en) Compositions comprising bacterial strains
CY1122523T1 (en) PEPTIDES AND PEPTIMOIMETES IN COMBINATION USES AND TREATMENTS FOR CANCER SUB-POPULATIONS
MD3307288T2 (en) Compositions comprising bacterial strains
MD3360559T2 (en) Compositions comprising bacterial strains
MD3204024T2 (en) Compositions comprising bacterial strains
UY37134A (en) HETEROARILE COMPOUNDS AND COMPOSITIONS THAT CONTAIN USEFUL AS PAD4 INHIBITORS
BR112017025005A2 (en) compositions comprising bacterial strains
CY1124406T1 (en) AZASETRONE FOR USE IN THE TREATMENT OF HEARING LOSS
CY1123290T1 (en) COMPOUNDS AND METHODS OF USE
SG10201808940WA (en) Nox inhibitor and nfкb inhibitor containing methoxyflavone
CR20160418A (en) NEW BICYCLE COMPOUNDS OF 7 LINKS
CY1117654T1 (en) POLYETHYLENE GLYCLENED APRELINE AND USES thereof
CY1122813T1 (en) SOLUBLE CD33 FOR THE TREATMENT OF MYELODYSPLASTIC SYNDROME (MDS)
EA202091731A1 (en) AUTOTAXIN INHIBITORS AND THEIR APPLICATIONS